Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.555 CAD -1.89% Market Closed
Market Cap: 128.5m CAD

Relative Value

There is not enough data to reliably calculate the relative value of CRDL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CRDL Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.4
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-5.6
Industry
20.9
Forward
-2.8
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-8.2
Industry
15.9
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-8.2
Industry
23.7
vs History
31
vs Industry
5
Median 3Y
3
Median 5Y
7.8
Industry
2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5
vs History
vs Industry
Median 3Y
-2
Median 5Y
-4
Industry
12.4
Forward
-3.4
vs History
vs Industry
Median 3Y
-2
Median 5Y
-4
Industry
15.9
Forward
-2.8
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-5.9
Industry
14.2
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-5.9
Industry
17.6
vs History
vs Industry
Median 3Y
-18
Median 5Y
-13.5
Industry
1.8

Multiples Across Competitors

CRDL Competitors Multiples
Cardiol Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cardiol Therapeutics Inc
TSX:CRDL
128.5m CAD 0 -3.6 -3 -2.9
US
Eli Lilly and Co
NYSE:LLY
717.8B USD 14.6 64.6 34.8 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
364B USD 4.1 16.7 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.5 18.8 12.4 14.1
CH
Roche Holding AG
SIX:ROG
206.6B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
179.2B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
160.2B GBP 3.9 27.4 130.5 196.7
US
Merck & Co Inc
NYSE:MRK
191.4B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
129.8B USD 2.1 16.5 7.2 10.1
P/E Multiple
Earnings Growth PEG
CA
Cardiol Therapeutics Inc
TSX:CRDL
Average P/E: 24.6
Negative Multiple: -3.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.6
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.7
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
18%
1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
17%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
30%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Cardiol Therapeutics Inc
TSX:CRDL
Average EV/EBITDA: 433.2
Negative Multiple: -3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.4
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.5
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Cardiol Therapeutics Inc
TSX:CRDL
Average EV/EBIT: 1 866.7
Negative Multiple: -2.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.7
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1